According to a recent study, there are significant delays in diagnosis and low implementation rates for treatment for hidradenitis suppurativa (HS).
Topical melatonin, rosuvastatin may reduce severity of mild-to-moderate plaque PsO
According to a recent study, topical melatonin and topical rosuvastatin were both effective in reducing the severity of mild-to-moderate plaque psoriasis.
New study shows dupilumab is efficacious, safe in treatment of AD in youth
According to a recent real-world study, dupilumab is safe and efficacious in treating moderate-to-severe atopic dermatitis (AD) in pediatric patients.
Guselkumab efficacious in PsO patients with history of cancer
According to a recent study, guselkumab is efficacious in patients with moderate-to-severe psoriasis and a history of cancer.
Lutikizumab effective in HS patients, new study shows
According to a recent study, lutikizumab 300 mg was shown to be more effective than placebo in hidradenitis suppurativa (HS) patients.
Study shows apremilast effective for moderate-to-severe plaque PsO in pediatric patients
According to a recent study, apremilast is effective for the treatment moderate-to-severe plaque psoriasis short-term in pediatric patients.
Blood monocyte count in PsO patients may predict early response to secukinumab
According to a recent study, plaque psoriasis patients with lower blood monocyte counts at baseline achieved early response and better outcomes when treated with secukinumab.
Skin microbiota may predict AD in infants
According to a recent study, biomarkers in the skin microbiota, antimicrobial peptides, and natural moisturizing factors may predict atopic dermatitis (AD) in infants.
Study shows liquid synthetic detergents best suited for AD patients
According to a recent study, liquid synthetic detergents are better suited for maintaining healthy skin barrier function in patients with atopic dermatitis (AD) than soaps.
Study shows most effective AD treatments may have greater risk of adverse events
According to a recent study, the most effective atopic dermatitis (AD) treatments may also have the greatest risk of adverse events.
HealthMinute.TV 